MedTrace Logo

Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality

NCT06112782 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-11-01

No results posted yet for this study

Summary

The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia. This study is intended to be a single arm study. Suitable subjects who meet all inclusion criteria and consented will undergo 3 in-office Keravive by Hydrafacial treatments at Day 0 and Weeks 4 and 8 in combination with daily application on Keravive Peptide Spray at home.

Subjects will be assessed at Day 0, and Weeks 4, 8, and 20 by investigators using the Norwood Scale (males), Ludwig Classification (females), and a series of Likert scales for ranking improvement in scalp health and hair quality.

Conditions

  • Androgenic Alopecia

Interventions

DEVICE

Keravive by Hydrafacial Treatments

Scalp hydradermabrasion

Sponsors & Collaborators

  • Skin Surgery Medical Group

    collaborator OTHER

  • ATS Clinical Research

    collaborator OTHER

  • Callender Center for Clinical Research

    collaborator OTHER

  • Rebecca Fitzgerald MD Inc.

    collaborator UNKNOWN

  • Beauty Health

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06112782 on ClinicalTrials.gov